

TURNING POINT THERAPEUTICS, INC. Reported by TOMBESI PAOLO

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 07/27/21 for the Period Ending 07/26/21

Address	10628 SCIENCE CENTER DRIVE, SUITE 200
	SAN DIEGO, CA, 92121
Telephone	858-926-5251
CIK	0001595893
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

Powered By EDGAR Online

https://www.edgar-online.com

© Copyright 2024, EDGAR Online LLC, a subsidiary of OTC Markets Group. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online LLC, a subsidiary of OTC Markets Group, Terms of Use.

FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer				
r bit i bit		(Check all applicable)				
TOMBESI PAOLO	Turning Point Therapeutics, Inc. [TPTX					
		Director 10% Owner				
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	_X_ Officer (give title below) Other (specify below)				
(Lust) (First) (Minute)		EVP & Chief Financial Officer				
C/O TURNING POINT	7/26/2021					
THERAPEUTICS, INC., 10628						
SCIENCE CENTER DRIVE, STE. 200						
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)				
SAN DIEGO, CA 92121		X _ Form filed by One Reporting Person Form filed by More than One Reporting Person				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)		Execution Date, if any	(Instr. 8)		or Disposed of (D) (Instr. 3, 4 and 5)			Following Reported Transaction(s) (Instr. 3 and 4)	Ownership Form:	Beneficial
			Code	v	Amount	(A) or (D)	Price		or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock	7/26/2021		Α		13600 <u>(1)</u>	A	\$0.00	13600	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(Instr. 3)	1	3. Trans. Date	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	Securities Beneficially Owned	Ownership Form of Derivative Security:	Beneficial Ownership (Instr. 4)
	Security		Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			Direct (D) or Indirect (I) (Instr. 4)	
Stock Option (right to buy)	\$62.63	7/26/2021	Α		61200		(2)	7/25/2031	Common Stock	61200	\$0.00	61200	D	

Explanation of Responses:

- (1) Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.
- (2) 25% of the shares vest on July 26, 2022 and 1/48th of the shares vest monthly thereafter over the next three years.

Reporting Owners

Reporting Owner Name / Address	Relationships							
Reporting Owner Warne / Address	Director	10% Owner	Officer	Other				
TOMBESI PAOLO C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, STE. 200 SAN DIEGO, CA 92121			EVP & Chief Financial Officer					

Signatures

/s/ Annette North, Attorney-in-Fact

7/27/2021

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

number.